TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01359150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
Study: NCT02507466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Variable conditions of stepping practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Variable conditions of stepping practice
Study: NCT03656042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (75mcg/0.3ml)
Description: Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment
Study: NCT03486769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMC stimulation
Description: stimulating premotor cortex with anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aIPS stimulation
Description: stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand motor task
Description: hand motor task for 30 minutes during transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand motor task
Description: hand motor task for 30 minutes during transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hand motor task
Description: hand motor task for 30 minutes during transcranial direct current stimulation
Study: NCT03663972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: articulation therapy
Description: children receive instruction in producing new sounds at the isolation, syllable and word level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: phonologic treatment
Description: children receive instruction in producing new sounds at the word level
Study: NCT02557867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
Study: NCT02507466

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Variable conditions of stepping practice
Study: NCT05040165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iceform liner and sleeve
Description: Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
Study: NCT04207593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxygen
Description: Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
Study: NCT03595982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procardia XL 30Mg
Description: Procardia XL 30 mg XL Q 12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procardia XL 60Mg
Description: Procardia XL 60 mg Q 24h
Study: NCT02425995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic intercondylar and posteromedial portal
Description: Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
Study: NCT00578890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical/surgical treatment versus medical treatment
Description: A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
Study: NCT00203996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWS supp
Description: SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
Study: NCT02554487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)
Description: Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
Study: NCT02848651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
Study: NCT02551276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Study: NCT01353326

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cormet
Description: Cementless hip resurfacing system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conserve
Description: Cemented hip resurfacing system
Study: NCT06350825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive prostatectomy or brachytherapy
Description: local treatment+SOC for metastatic prostate cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT+second-generation antiandrogens ± chemotherapy
Description: SOC(Triplet or doublet therapy) for mHSPC
Study: NCT03122899

Intervention type: DEVICE
Group type: OTHER
Intervention: SIJ fusion with iFuse-3D
Description: Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).

Intervention type: DEVICE
Group type: OTHER
Intervention: SIJ fusion with iFuse-3D
Description: Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
Study: NCT02412033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 µg misoprostol vaginally 3 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive placebo
Study: NCT01574040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of stair climbing
Description: Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a low-salt soup alternative for the 'soup of the day'
Description: Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a low-fat alternative for the butter croissants
Description: Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations
Description: Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
Study: NCT01402791

Intervention type: OTHER
Intervention: Questionnaires
Description: All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
Study: NCT01700205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of Formula
Description: infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Formula
Description: infant formula
Study: NCT01260896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study: NCT04160936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine Injectable Product
Description: Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
Study: NCT02188836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Description: Electromagnetic stimulation with a new device produced by the investigators for this study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
Study: NCT02394106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 1000 ml, administered once
Study: NCT01401231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation psychotherapy
Description: Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Continued usual care (could include referral for medication or psychotherapy)
Study: NCT02884245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens
Description: The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
Study: NCT02575924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential medium
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential medium
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential medium
Description: administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-step medium
Description: administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-step medium
Description: administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-step medium
Description: administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
Study: NCT00491894

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Glycopyrrolate Liquid
Description: Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
Study: NCT03471585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
Study: NCT01212744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG
Description: 0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
Study: NCT01262339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTX-A
Description: 100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
Study: NCT02477813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
Study: NCT02438007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galeterone
Description: 2550 mg galeterone tablets once daily PO
Study: NCT01974206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: intramuscular injection
Study: NCT02438007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg enzalutamide capsules once daily PO
Study: NCT03568409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABO-GLYC
Description: 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ABO-GLYC Placebo
Description: 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
Study: NCT04162457

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
Study: NCT01968967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection every 2 weeks for 12 months
Study: NCT02098837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir 50mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir 50mg once daily
Study: NCT00571649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban placebo
Description: Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin placebo
Description: Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
Study: NCT01974206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study: NCT04216472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT03441035

Intervention type: OTHER
Intervention: General anesthesia and surgery (liver transplantation)
Description: The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.

Intervention type: OTHER
Intervention: General anesthesia and surgery (liver transplantation)
Description: The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.

Intervention type: OTHER
Intervention: General anesthesia and surgery (liver transplantation)
Description: The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
Study: NCT01894048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qvar® (beclometasone dipropionate HFA)
Description: Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
Study: NCT02224443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group C , Normal saline infusion will be given with the same infusion volume as group A and B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate
Description: Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane
Description: Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
Study: NCT03500016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: See under arm description.
Study: NCT01373255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal iliac catheterization
Description: Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
Study: NCT01210963

Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
Study: NCT02488135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floseal Hemostatic Matrix
Description: Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Nasal Packing
Description: Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.